Genmab (GMAB) news
Recent news
Genmab: UBS raises target price to DKK 2700 from DKK 2600
UBS has raised its price target for Genmab A/S (CSE:GEN) (NASDAQ:GMAB) to DKK2,750.00 from DKK2,700.00, while maintaining its Buy rating . The adjustment reflects the investment bank’s confidence in Genmab’s upcoming pipeline developments, particularly in 2026, when three Phase 3 programs are…
AInvest Wire · Aug 7, 2026Genmab shares up 6% after Q2 revenue beat, FY guidance hike
AInvest Wire · Aug 7, 2026Genmab: TD Cowen raises target price to DKK 2892 from DKK 2851
TD Cowen has raised its price target for Genmab A/S (NASDAQ:GMAB) to DKK 2892 from DKK 2851, reflecting increased confidence in the company’s drug pipeline and strategic direction. The upgrade aligns with recent developments, including the acquisition of MRUS for $97 per share, or approximately $8…
AInvest Wire · Aug 7, 2026Genmab sees FY operating income $1.07B to $1.39B, est. $1.22B
Genmab A/S (GMAB) reported fiscal year operating income in the range of $1.07 billion to $1.39 billion, with an estimated midpoint of $1.22 billion. This performance reflects the company’s ongoing focus on its core therapeutic areas and strategic business operations. The operating income aligns…
AInvest Wire · Aug 6, 2026Genmab - net sales of Darzalex by J&J $8.17 bln for first six months of 2026, up 21%
AInvest Wire · Aug 6, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.